Impact of Infections in Patients with Acute Myeloid Leukemia Receiving Cytarabine+ Daunorubicin (7+3) Versus Azacitidine and Venetoclax during Induction Chemotherapy
DOI:
https://doi.org/10.70749/ijbr.v3i1.469Keywords:
Azacitidine, Venetoclax, Induction, Acute Myeloid Leukemia, Infections, Pakistan, Hematological MalignancyAbstract
Acute myeloid leukemia (AML) remains a challenging hematologic malignancy, with infections, treatment-related toxicity, and multidrug-resistant (MDR) organisms significantly contributing to high mortality, particularly in resource-limited settings. This study examined infection patterns, MDR prevalence, and induction outcomes in AML patients receiving standard regimens, including Cytarabine-anthracycline (7+3) and azacitidine-venetoclax (Aza/Ven), at a tertiary hospital in Pakistan. In this observational study, 176 AML patients aged ≥18 years treated from January 2018 to December 2023 were analyzed. Patients on the 7+3 (65.3%) and Aza/Ven (34.7%) regimens were assessed for demographics, clinical status, infection rates, organism profiles, antibiotic resistance, and survival outcomes using Kaplan‒Meier and Cox regression models. Patients on the 7+3 regimen experienced significantly higher neutropenia and infection rates (p<0.001). Among 106 isolates from blood cultures, 12.5% were MDR, with 63% being carbapenem-resistant Enterobacteriaceae (CRE). The Aza/Ven group exhibited a higher induction-related mortality rate (31.1%) compared to 7+3 (21.7%, p=0.03). Adjusted analysis revealed a six-fold increased risk of death with the Aza/Ven regimen (p<0.001). This study highlights the significant burden of infections and MDR organisms in AML patients, particularly those on Aza/Ven, often reserved for older or high-risk patients. The findings underscore the need for robust infection prevention, stringent antibiotic stewardship, and tailored treatments to optimize outcomes. Further research is essential to refine induction regimens that balance efficacy with infection-related risks, especially in resource-limited settings.
Downloads
References
Atallah, E., Cortes, J., O'Brien, S., Pierce, S., Rios, M. B., Estey, E., Markman, M., Keating, M., Freireich, E. J., & Kantarjian, H. (2007). Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood, 110(10), 3547-3551. https://doi.org/10.1182/blood-2007-06-095844
Solana-Altabella, A., Rodríguez-Veiga, R., Martínez-Cuadrón, D., & Montesinos, P. (2024). A systematic review of venetoclax for the treatment of unfit AML patients in real-world: Is all that glitters gold? Annals of Hematology. https://doi.org/10.1007/s00277-024-05891-w
Lech-Maranda, E., Seweryn, M., Giebel, S., Holowiecki, J., Piatkowska-Jakubas, B., Wegrzyn, J., Skotnicki, A., Kielbinski, M., Kuliczkowski, K., Paluszewska, M., Jedrzejczak, W. W., Dutka, M., Hellmann, A., Flont, M., Zdziarska, B., Palynyczko, G., Konopka, L., Szpila, T., Gawronski, K., … Robak, T. (2010). Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish adult leukemia group (PALG). International Journal of Infectious Diseases, 14(2), e132-e140. https://doi.org/10.1016/j.ijid.2009.02.021
Niscola, P., Mazzone, C., Fratoni, S., Ardu, N. R., Cesini, L., Giovannini, M., Ottone, T., Anemona, L., Voso, M. T., & De Fabritiis, P. (2023). Acute myeloid leukemia with NPM1 mutation and disseminated leukemia cutis: Achievement of molecular complete remission by Venetoclax/Azacitidine combination in a very old patient. Acta Haematologica, 146(5), 408-412. https://doi.org/10.1159/000531101
Philip, C., George, B., Ganapule, A., Korula, A., Jain, P., Alex, A. A., Lakshmi, K. M., Sitaram, U., Abubacker, F. N., Abraham, A., Viswabandya, A., Srivastava, V. M., Srivastava, A., Balasubramanian, P., & Mathews, V. (2015). Acute myeloid leukaemia: Challenges and real world data from India. British Journal of Haematology, 170(1), 110-117. https://doi.org/10.1111/bjh.13406
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., Rowe, J. M., Lazarus, H. M., & Tallman, M. S. (2009). Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361(13), 1249-1259. https://doi.org/10.1056/nejmoa0904544
Magiorakos, A., Srinivasan, A., Carey, R., Carmeli, Y., Falagas, M., Giske, C., Harbarth, S., Hindler, J., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D., Rice, L., Stelling, J., Struelens, M., Vatopoulos, A., Weber, J., & Monnet, D. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clinical Microbiology and Infection, 18(3), 268-281. https://doi.org/10.1111/j.1469-0691.2011.03570.x
Kumar, H., Mehra, N., Ganesan, P., Radhakrishnan, V., Dhanushkodi, M., P K, J., Ganesan, T. S., Shankar, S. K., Sagar, T. G., & Kannan, K. (2018). Patterns of infection and mortality associated with intensive AML induction therapy: 10 year experience from a tertiary cancer centre in India. Blood, 132(Supplement 1), 4008-4008. https://doi.org/10.1182/blood-2018-99-119919
Sidhu, S. K., Malhotra, S., Devi, P., & Tuli, A. K. (2016). Significance of coagulase negative Staphylococcus from blood cultures: persisting problems and partial progress in resource constrained settings. Iranian journal of microbiology, 8(6), 366–371.
Khan, F., Kirmani, S., Siddiqui, N., Sultan, A., Sami, H., Mahtab, M., & Khan, H. M. (2015). CoNS in blood culture: contaminants or pathogens. Int J Curr Microbiol App Sci, 1, 88-94.
Osmani, A. H., Jabbar, A. A., Gangwani, M. K., & Hassan, B. (2017). Outcomes of High Risk Patients with Febrile Neutropenia at a Tertiary Care Center. Asian Pacific Journal of Cancer Prevention : APJCP, 18(10), 2741–2745. https://doi.org/10.22034/APJCP.2017.18.10.2741
Rajme‐López, S., Tello‐Mercado, A., Ortíz‐Brizuela, E., Martínez‐Guerra, B., Tamez‐Torres, K., Román‐Montes, C., González‐Lara, M., & Ponce‐de‐León, A. (2024). Clinical and Microbiological characteristics of febrile Neutropenia during induction chemotherapy in adults with acute leukemia. Cancer Reports, 7(8). https://doi.org/10.1002/cnr2.2129
Tariq, R, Sajid, N, Masood, M, Shahid, A. (2021). Frequency of induction-related mortality in patients of Acute Myeloid Leukemia - Experience from a Resource Limited Country. Asian Hematology Research Journal, 4(3), 241-50.
Pandian, J., Raghavan, V., Manuprasad, A., Shenoy, P. K., & Nair, C. K. (2020). Infection at diagnosis—a unique challenge in acute myeloid leukemia treatment in developing world. Supportive Care in Cancer, 28(11), 5449-5454. https://doi.org/10.1007/s00520-020-05379-z
Bahl, A., Sharma, A., Raina, V., Kumar, L., Bakhshi, S., Gupta, R., & Kumar, R. (2015). Long-term outcomes for patients with acute myeloid leukemia: A single-center experience from AIIMS, India. Asia-Pacific Journal of Clinical Oncology, 11(3), 242-252. https://doi.org/10.1111/ajco.12333
Niscola, P., Mazzone, C., Fratoni, S., Ardu, N. R., Cesini, L., Giovannini, M., Ottone, T., Anemona, L., Voso, M. T., & De Fabritiis, P. (2023). Acute myeloid leukemia with NPM1 mutation and disseminated leukemia cutis: Achievement of molecular complete remission by Venetoclax/Azacitidine combination in a very old patient. Acta Haematologica, 146(5), 408-412. https://doi.org/10.1159/000531101
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
